Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25132769 | 0.95 | CTSL (0.45) | ALDH1A1L3MBTL1MAPK1MAPTHPGD | |
| SCHEMBL31072143 | 0.95 | CTSL (0.45) | ALDH1A1L3MBTL1MAPK1MAPTHPGD | |
| SCHEMBL31072120 | 0.95 | CTSL (0.45) | ALDH1A1L3MBTL1MAPK1MAPTHPGD | |
| SCHEMBL25132759 | 0.95 | CTSL (0.45) | ALDH1A1L3MBTL1MAPK1MAPTHPGD | |
| SCHEMBL18686281 | 0.90 | L3MBTL1 (0.45) | ALDH1A1L3MBTL1MAPK1MAPTHPGD | |
| SCHEMBL9089657 | 0.89 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1MAPK1MAPTHPGD | |
| SCHEMBL1455946 | 0.88 | L3MBTL1 (0.45) | ALDH1A1L3MBTL1MAPK1MAPTHPGD | |
| SCHEMBL30315266 | 0.87 | L3MBTL1 (0.44) | ALDH1A1L3MBTL1MAPK1MAPTHPGD | |
| SCHEMBL29077734 | 0.87 | L3MBTL1 (0.50) | ALDH1A1L3MBTL1MAPK1MAPTHPGD | |
| SCHEMBL28956076 | 0.86 | L3MBTL1 (0.47) | ALDH1A1L3MBTL1MAPK1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4656201-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. | 2025-06-19 | — | — | US | disclosed |
| CN-115873020-B | RAS inhibitors | 锐新医药公司 | 2025-06-13 | — | — | CN | disclosed |
| US-20250051306-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-02-13 | — | — | US | disclosed |
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-27 | — | — | US | disclosed |
| EP-4308575-A1 | MACROCYCLES AS CFTR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2024-01-24 | — | — | EP | disclosed |
| CN-116981672-A | Macrocyclic compounds as CFTR modulators | 爱杜西亚药品有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-11739074-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739074-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| EP-4054720-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| CN-114901366-A | RAS inhibitors | 锐新医药公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2022060583-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. (US) | 2022-03-24 | — | — | WO | disclosed |
| WO-2021257736-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2021-12-23 | — | — | WO | disclosed |
| CN-113366107-A | Antibacterial antisense agents | 佩达尼斯治疗有限公司 | 2021-09-07 | — | — | CN | disclosed |
| US-20210214374-A1 | COMPOUNDS AND COMPOSITIONS FOR OCULAR DELIVERY | Graybug Vision, Inc. (US) | 2021-07-15 | — | — | US | disclosed |
| US-20210130326-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
| US-20210130326-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
| US-20210040111-A1 | DRUGS TO TREAT OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2021-02-11 | — | — | US | disclosed |
| US-6362165-B1 | Hydroxyphenyl derivatives with HIV integrase inhibitory properties | PHARMACOR INC. (CA) | 2002-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040111-A1 | DRUGS TO TREAT OCULAR DISORDERS | PDE6C, AGER, PDE6A | ALDH1A1 761/4885L3MBTL1 4382/4885MAPK1 1067/4885 |
| US-20250051306-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | ALDH1A1 4437/4885L3MBTL1 3097/4885MAPK1 352/4885 |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | SOS1, PPM1D, PTPN1 | ALDH1A1 4135/4885L3MBTL1 819/4885MAPK1 202/4885 |
| US-11739074-B2 | Ras inhibitors | KRAS, NRAS, HRAS | ALDH1A1 3951/4885L3MBTL1 3587/4885MAPK1 162/4885 |
| US-20210130326-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | ALDH1A1 4437/4885L3MBTL1 3097/4885MAPK1 352/4885 |
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | CFTR, PKD1, ARRB1 | ALDH1A1 2257/4885L3MBTL1 4504/4885MAPK1 2666/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | ALDH1A1 4528/4885L3MBTL1 1005/4885MAPK1 769/4885 |
| US-20210214374-A1 | COMPOUNDS AND COMPOSITIONS FOR OCULAR DELIVERY | KDR, RB1, PDE6C | ALDH1A1 2125/4885L3MBTL1 4766/4885MAPK1 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.